{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:43:54Z","timestamp":1792532634324,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016460","name":"Jayne Koskinas Ted Giovanis Foundation for Health and Policy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Toxicol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Iron oxide nanoparticle formulations are widely used in clinical applications and have recently been explored for hyperthermia therapy, cancer imaging and treatment. Here, we report the effects of intravenously injected pegylated or poly acrylic acid decorated iron oxide nanoparticles coated with hydroxyethyl starch (HES) on host immune system and organs. These particles were compared with sucrose coated iron oxide nanoparticle (Venofer<jats:sup>\u00ae<\/jats:sup>) and the coating compound HES\u2013both FDA approved agents\u2013alongside non-iron oxide polystyrene nanoparticles coated with HES (micromer<jats:sup>\u00ae<\/jats:sup>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Toxicity analysis was performed in healthy female normal FVB\/NJ mice 60 days after nanoparticle injection, with complete blood analysis conducted at multiple time-points. In a separate cohort, nanoparticle biodistribution 24 h post-intravenous injection was evaluated using a HER2 overexpressing breast cancer mouse model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Toxicity analysis revealed no adverse effects on liver or kidneys with any of the tested formulations after 60 days. Immune cell perturbations were observed at early time points following iron oxide nanoparticle injection but normalized by the study endpoint. Biodistribution analysis demonstrated that the nanoparticle coating dictated their accumulation across various organs, with significant tumor accumulation observed for pegylated iron oxide nanoparticles and Venofer<jats:sup>\u00ae<\/jats:sup>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Iron oxide nanoparticle formulations exert a transient effect on the host immune system and some exhibit tumor accumulation, suggesting their potential for further development in cancer imaging and treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/ftox.2025.1673416","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:29:44Z","timestamp":1760419784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Intravenously administered iron oxide nanoparticles with different coatings reversibly perturb immune cells in peripheral blood without inducing toxicity in mice"],"prefix":"10.3389","volume":"7","author":[{"given":"Preethi","family":"Korangath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Gr\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ivkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.drudis.2019.09.020","article-title":"Iron oxide nanoparticles for therapeutic applications","volume":"25","author":"Alphand\u00e9ry","year":"2020","journal-title":"Drug Discov. Today"},{"key":"B2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/02656736.2015.1005178","article-title":"Magnetic nanoparticle hyperthermia enhances radiation therapy: a study in mouse models of human prostate cancer","volume":"31","author":"Attaluri","year":"2015","journal-title":"Int. J. Hyperth."},{"key":"B3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/02656736.2020.1798514","article-title":"Magnetic nanoparticle hyperthermia for treating locally advanced unresectable and borderline resectable pancreatic cancers: the role of tumor size and eddy-current heating","volume":"37","author":"Attaluri","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"B4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ajh.26124","article-title":"Intravenous ferric derisomaltose for the treatment of iron deficiency anemia","volume":"96","author":"Auerbach","year":"2021","journal-title":"Am. J. Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/molecules25010112","article-title":"The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine","volume":"25","author":"Bayda","year":"2019","journal-title":"Molecules"},{"key":"B6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/nano8060410","article-title":"Biodistribution and toxicity of micellar platinum nanoparticles in mice via intravenous administration","volume":"8","author":"Brown","year":"2018","journal-title":"Nanomater. (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/nano11081950","article-title":"Iron oxide nanoparticles as Theranostic agents in cancer immunotherapy","volume":"11","author":"Canese","year":"2021","journal-title":"Nanomater. (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2001451","DOI":"10.1002\/adhm.202001451","article-title":"Advances in magnetic nanoparticle-mediated cancer immune-theranostics","volume":"10","author":"Cheng","year":"2021","journal-title":"Adv. Healthc. Mater"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1016\/j.biomaterials.2011.05.024","article-title":"Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles","volume":"32","author":"Cole","year":"2011","journal-title":"Biomaterials"},{"key":"B10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","article-title":"Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications","volume":"138","author":"Dadfar","year":"2019","journal-title":"Adv. drug Deliv. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4911205","DOI":"10.1155\/2022\/4911205","article-title":"Iron chelators in treatment of iron overload","volume":"5","author":"Entezari","year":"2022","journal-title":"J. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bjhh.2015.08.012","article-title":"Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia","volume":"37","author":"Friedrisch","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"B13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.6004\/jnccn.2014.0069","article-title":"Should the ASCO\/ASH guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?","volume":"12","author":"Gafter-Gvili","year":"2014","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12885-016-2686-2","article-title":"Is there any role of intravenous iron for the treatment of anemia in cancer?","volume":"16","author":"Gemici","year":"2016","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.7150\/ntno.84255","article-title":"Spatial analysis of nanoparticle distribution in human breast xenografts reveals nanoparticles targeted to cancer cells localized with tumor-associated stromal cells","volume":"7","author":"Healy","year":"2023","journal-title":"Nanotheranostics"},{"key":"B18","unstructured":"Methods and compositions for administration of iron\n          \n          \n            \n              Helenek\n              M. J.\n            \n            \n              Tokars\n              M. L.\n            \n            \n              Lawrence\n              P. R.\n            \n          \n          United States Patent and Trademark Office\n          \n          2023"},{"key":"B17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2217\/nnm.14.203","article-title":"Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors","volume":"10","author":"Iv","year":"2015","journal-title":"Nanomedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/biot.201100045","article-title":"Cancer hyperthermia using magnetic nanoparticles","volume":"6","author":"Kobayashi","year":"2011","journal-title":"Biotechnol. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"eaay1601","DOI":"10.1126\/sciadv.aay1601","article-title":"Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer","volume":"6","author":"Korangath","year":"2020","journal-title":"Sci. Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"10509","DOI":"10.1021\/acsnano.3c12064","article-title":"Iron oxide nanoparticles inhibit tumor progression and suppress lung metastases in mouse models of breast cancer","volume":"18","author":"Korangath","year":"2024","journal-title":"ACS Nano"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00520-017-3672-1","article-title":"Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies","volume":"25","author":"Lebrun","year":"2017","journal-title":"Support Care Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s12325-020-01323-z","article-title":"Iron sucrose: a wealth of experience in treating iron deficiency","volume":"37","author":"Macdougall","year":"2020","journal-title":"Adv. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jconrel.2020.05.027","article-title":"One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility","volume":"324","author":"Mohammadpour","year":"2020","journal-title":"J. Control Release"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa1209759","article-title":"Hydroxyethylstarchorsalineforfluidresuscitation inintensivecare","volume":"367","author":"Myburgh","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.2147\/IJN.S415063","article-title":"In vivo biodistribution and clearance of magnetic iron oxide nanoparticles for medical applications","volume":"18","author":"Nowak-Jary","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/02656736.2019.1685686","article-title":"Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer","volume":"36","author":"Oei","year":"2019","journal-title":"Int. J. Hyperth."},{"key":"B28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jat.3232","article-title":"Distribution and immunotoxicity by intravenous injection of iron nanoparticles in a murine model","volume":"36","author":"Park","year":"2016","journal-title":"J. Appl. Toxicol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1021\/acsnano.0c08913","article-title":"Enhancing immunity with nanomedicine: employing nanoparticles to harness the immune system","volume":"15","author":"Perciani","year":"2021","journal-title":"ACS Nano"},{"key":"B30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1055\/s-0031-1296304","article-title":"The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review","volume":"60","author":"Qunibi","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"B31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/ph17030300","article-title":"Magnetic hyperthermia therapy for high-grade glioma: a state-of-the-art review","volume":"17","author":"Rodriguez","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1097\/MS9.0000000000001717","article-title":"Iron chelators: as therapeutic agents in diseases","volume":"86","author":"Salimi","year":"2024","journal-title":"Ann. Med. Surg. (Lond)."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1038\/s41598-018-23317-2","article-title":"Physical characterization and in vivo organ distribution of coated iron oxide nanoparticles","volume":"8","author":"Sharma","year":"2018","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-021-03729-3","article-title":"Magnetic hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent\/progressive glioblastoma: a systematic review","volume":"152","author":"Shirvalilou","year":"2021","journal-title":"J. Neurooncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.addr.2020.06.025","article-title":"Cancer therapy with iron oxide nanoparticles: agents of thermal and immune therapies","author":"Soetaert","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1039\/D4NA00561A","article-title":"Dendritic cell activation by iron oxide nanoparticles depends on the extracellular environment","volume":"7","author":"Song","year":"2024","journal-title":"Nanoscale Adv."},{"key":"B37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.kint.2016.12.037","article-title":"Current and potential imaging applications of ferumoxytol for magnetic resonance imaging","volume":"92","author":"Toth","year":"2017","journal-title":"Kidney Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ajh.27220","article-title":"Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions","volume":"99","author":"Van Doren","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12951-016-0162-4","article-title":"Immunotoxicity assessment of CdSe\/ZnS quantum dots in macrophages, lymphocytes and BALB\/c mice","volume":"14","author":"Wang","year":"2016","journal-title":"J. Nanobiotechnology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1038\/s41598-017-03015-1","article-title":"Comparisons of the biodistribution and toxicological examinations after repeated intravenous administration of silver and gold nanoparticles in mice","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Toxicology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftox.2025.1673416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:29:45Z","timestamp":1760419785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftox.2025.1673416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":40,"alternative-id":["10.3389\/ftox.2025.1673416"],"URL":"https:\/\/doi.org\/10.3389\/ftox.2025.1673416","relation":{},"ISSN":["2673-3080"],"issn-type":[{"value":"2673-3080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"1673416"}}